[go: up one dir, main page]

IL149139A0 - Pharmaceutical compositions containing metformin and glyburide - Google Patents

Pharmaceutical compositions containing metformin and glyburide

Info

Publication number
IL149139A0
IL149139A0 IL14913900A IL14913900A IL149139A0 IL 149139 A0 IL149139 A0 IL 149139A0 IL 14913900 A IL14913900 A IL 14913900A IL 14913900 A IL14913900 A IL 14913900A IL 149139 A0 IL149139 A0 IL 149139A0
Authority
IL
Israel
Prior art keywords
glyburide
pharmaceutical compositions
compositions containing
containing metformin
metformin
Prior art date
Application number
IL14913900A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/432,465 external-priority patent/US6586438B2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL149139A0 publication Critical patent/IL149139A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14913900A 1999-11-03 2000-10-13 Pharmaceutical compositions containing metformin and glyburide IL149139A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/432,465 US6586438B2 (en) 1999-11-03 1999-11-03 Antidiabetic formulation and method
US09/460,920 US7598262B2 (en) 1999-11-03 1999-12-14 Method for treating diabetes
PCT/US2000/028311 WO2001032157A2 (en) 1999-11-03 2000-10-13 Pharmaceutical composition comprising a combination of metformin and glibenclamide

Publications (1)

Publication Number Publication Date
IL149139A0 true IL149139A0 (en) 2002-11-10

Family

ID=27029501

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14913900A IL149139A0 (en) 1999-11-03 2000-10-13 Pharmaceutical compositions containing metformin and glyburide

Country Status (23)

Country Link
EP (1) EP1229918B1 (et)
JP (1) JP5183844B2 (et)
KR (1) KR20070089259A (et)
CN (1) CN1450902A (et)
AR (1) AR026356A1 (et)
AT (1) ATE390140T1 (et)
AU (1) AU780106B2 (et)
BR (1) BR0015294A (et)
CA (1) CA2389928C (et)
EE (1) EE05260B1 (et)
HU (1) HU229352B1 (et)
IL (1) IL149139A0 (et)
LT (1) LT5058B (et)
LV (1) LV12910B (et)
MX (1) MXPA02004282A (et)
NO (1) NO330026B1 (et)
NZ (1) NZ518278A (et)
PL (1) PL199278B1 (et)
RU (1) RU2275915C2 (et)
SK (1) SK287810B6 (et)
TW (1) TWI280125B (et)
UY (1) UY26424A1 (et)
WO (1) WO2001032157A2 (et)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
WO2003011273A1 (en) * 2001-07-31 2003-02-13 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Metformin in the treatment of hyperglycemic conditions
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
JP2007509865A (ja) * 2003-10-30 2007-04-19 ティオガ ファーマシュウティカルズ，インコーポレイテッド 神経障害の治療における選択的オピエート受容体調節物質の使用
SG149814A1 (en) * 2003-12-19 2009-02-27 Omega Bio Pharma Ip3 Ltd Compositions and methods for treating diabetes
BRPI0510613A (pt) * 2004-05-03 2007-10-30 Omega Bio Pharma Ip3 Ltd cisteaminas para tratar complicações de hipercolesterolemia e diabete
CN101801351B (zh) 2007-07-19 2012-12-12 武田药品工业株式会社 包含阿格列汀和盐酸二甲双胍的固体制剂
CN101801371B (zh) 2007-09-10 2012-11-28 詹森药业有限公司 可用作sglt抑制剂的化合物的制备方法
RU2372911C1 (ru) * 2008-03-12 2009-11-20 Николай Евгеньевич Староверов Полиморфная аналоговая терапия
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
PT2349324T (pt) 2008-10-17 2017-12-06 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
WO2011058083A1 (de) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten, ein insulin und methionin
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
NZ703128A (en) 2010-05-11 2016-04-29 Janssen Pharmaceutica Nv Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
RS55378B1 (sr) 2010-08-30 2017-03-31 Sanofi Aventis Deutschland Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
AU2012213435B2 (en) * 2011-02-02 2017-03-30 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US20120277147A1 (en) * 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN110804017A (zh) * 2019-10-31 2020-02-18 天津大学 磺酰脲化合物与二甲双胍成盐、制备方法和应用
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE3833439A1 (de) * 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
CZ298469B6 (cs) 1997-06-18 2007-10-10 Smithkline Beecham Plc Farmaceutický prostredek obsahující 5-[4-/2-(N-methyl-N-(2-pyridyl)amino)ethoxy/benzyl]thiazolidin-2,4-dion a metformin, a lécivo pro lécení diabetesmellitus
DE69822505T2 (de) * 1997-12-08 2005-01-20 Bristol-Myers Squibb Co. Neue metformin-salze und verfahren
EP0974356B1 (en) * 1998-07-15 2003-09-24 Merck Sante Tablets comprising a combination of metformin and glibenclamide
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins

Also Published As

Publication number Publication date
PL364885A1 (en) 2004-12-27
NO20022087D0 (no) 2002-05-02
LT5058B (lt) 2003-09-25
EE200200242A (et) 2003-12-15
TWI280125B (en) 2007-05-01
BR0015294A (pt) 2003-07-15
AU1082601A (en) 2001-05-14
LT2002063A (en) 2003-06-25
EE05260B1 (et) 2010-02-15
PL199278B1 (pl) 2008-09-30
CN1450902A (zh) 2003-10-22
EP1229918A2 (en) 2002-08-14
CA2389928A1 (en) 2001-05-10
RU2002114820A (ru) 2004-03-10
AU780106B2 (en) 2005-03-03
UY26424A1 (es) 2001-05-31
LV12910B (en) 2003-05-20
RU2275915C2 (ru) 2006-05-10
SK5002002A3 (en) 2004-05-04
JP5183844B2 (ja) 2013-04-17
WO2001032157A3 (en) 2002-01-24
HU229352B1 (en) 2013-11-28
HUP0300218A3 (en) 2006-02-28
EP1229918B1 (en) 2008-03-26
MXPA02004282A (es) 2003-02-17
NZ518278A (en) 2004-10-29
WO2001032157A2 (en) 2001-05-10
NO20022087L (no) 2002-06-24
NO330026B1 (no) 2011-02-07
KR20070089259A (ko) 2007-08-30
AR026356A1 (es) 2003-02-05
SK287810B6 (sk) 2011-10-04
ATE390140T1 (de) 2008-04-15
JP2003519621A (ja) 2003-06-24
HUP0300218A2 (hu) 2003-06-28
CA2389928C (en) 2010-03-23

Similar Documents

Publication Publication Date Title
IL149139A0 (en) Pharmaceutical compositions containing metformin and glyburide
IL149138A0 (en) Pharmaceutical compositions containing metformin
HUP0203939A3 (en) Pharmaceutical compounds and compositions containing them and their use
HUP0203378A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
IL150383A0 (en) Glyburide and pharmaceutical compositions containing the same
HUP0200714A3 (en) Pharmaceutical compounds, pharmaceutical compositions containing them and their use
PT1213020E (pt) Compostos e composições farmacêuticas com actividade supressora do apetite
HUP0203700A3 (en) N-substituted 2-cyanopyrrolidines and their use as antidiabetic agents and pharmaceutical compositions containing them
IL155196A0 (en) Benzamide derivatives and pharmaceutical compositions containing the same
HUP0204081A3 (en) 4-pyrimidinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use
HUP0001309A3 (en) 1-phenyl-4-benzylpiperazines and pharmaceutical compositions containing them
IL133097A0 (en) Aroyl-piperazine derivatives pharmaceutical compositions containing the same and the use thereof
HUP0203194A3 (en) Phenylpiperazines, pharmaceutical compositions containing them and their use
HUP0203735A3 (en) 4-pyridinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use
HUP0000137A3 (en) Controller-release pharmaceutical composition containing anangetics
HUP0105204A3 (en) Substituted phenethylamine derivatives and pharmaceutical compositions containing them
HUP0200747A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
IL137505A (en) Pharmaceutical compositions containing tramadol
HUP0100085A3 (en) Biphenylamidine derivatives and pharmaceutical compositions containing them
HUP0200055A3 (en) 16-hydroxyestrienes and pharmaceutical compositions containing the same
HUP9802132A3 (en) Biphenyl-sulfonyl-cyanamides, their use and pharmaceutical compositions containing them
HUP0201910A3 (en) Novel aminobenzophenones, pharmaceutical compositions containing them and their use
HUP0003189A2 (en) Pharmaceutical composition comprising fexofenadine and its derivatives
HUP0101733A3 (en) Pharmaceutical compositions containing sulfonyl-dipeptides and their use
HUP0001940A3 (en) Benzisothiazole derivatives, their use and pharmaceutical compositions containing them